Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 46 active drug candidates.
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route.
Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer.
The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.
The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc.
entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!